{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:21:46Z","timestamp":1788322906274,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s12185-025-03958-6","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T21:48:59Z","timestamp":1741038539000},"page":"73-82","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Extramedullary disease in multiple myeloma at diagnosis and over the course of the disease"],"prefix":"10.1007","volume":"122","author":[{"given":"Murad","family":"Guliyev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Tunc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umut","family":"Y\u0131lmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selin","family":"Kucukyurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz","family":"Ozmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tugrul","family":"Elverdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet Emre","family":"Eskazan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhlis Cem","family":"Ar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y\u0131ld\u0131z","family":"Ayd\u0131n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayse","family":"Salihoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"key":"3958_CR1","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/bjh.17338","volume":"194","author":"L Rosi\u00f1ol","year":"2021","unstructured":"Rosi\u00f1ol L, Beksac M, Zamagni E, et al. Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. Br J Haematol. 2021;194:496\u2013507.","journal-title":"Br J Haematol"},{"key":"3958_CR2","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/annonc\/mdp329","volume":"21","author":"M Varettoni","year":"2010","unstructured":"Varettoni M, Corso A, Pica G, et al. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol. 2010;21:325\u201330. https:\/\/doi.org\/10.1093\/annonc\/mdp329.","journal-title":"Ann Oncol"},{"key":"3958_CR3","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1200\/JCO.2011.34.9290","volume":"29","author":"J Blad\u00e9","year":"2011","unstructured":"Blad\u00e9 J, Fern\u00e1ndez de Larrea C, Rosi\u00f1ol L, et al. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol. 2011;29:3805\u201312. https:\/\/doi.org\/10.1200\/JCO.2011.34.9290.","journal-title":"J Clin Oncol"},{"key":"3958_CR4","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3324\/haematol.2012.065698","volume":"97","author":"SZ Usmani","year":"2012","unstructured":"Usmani SZ, Heuck C, Mitchell A, et al. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica. 2012;97:1761\u20137. https:\/\/doi.org\/10.3324\/haematol.2012.065698.","journal-title":"Haematologica"},{"key":"3958_CR5","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/leu.2011.29","volume":"25","author":"KD Short","year":"2011","unstructured":"Short KD, Rajkumar SV, Larson D, et al. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia. 2011;25:906\u20138.","journal-title":"Leukemia"},{"key":"3958_CR6","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1111\/bjh.13383","volume":"169","author":"M Weinstock","year":"2015","unstructured":"Weinstock M, Aljawai Y, Morgan EA, et al. Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. Br J Haematol. 2015;169:851\u20138. https:\/\/doi.org\/10.1111\/bjh.13383.","journal-title":"Br J Haematol"},{"key":"3958_CR7","doi-asserted-by":"publisher","first-page":"890","DOI":"10.3324\/haematol.2017.178434","volume":"103","author":"N Gagelmann","year":"2018","unstructured":"Gagelmann N, Eikema DJ, Iacobelli S, et al. Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: A study from the chronic malignancies working party of the EBMT. Haematologica. 2018;103:890\u20137. https:\/\/doi.org\/10.3324\/haematol.2017.178434.","journal-title":"Haematologica"},{"key":"3958_CR8","doi-asserted-by":"publisher","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","volume":"118","author":"E Zamagni","year":"2011","unstructured":"Zamagni E, Patriarca F, Nanni C, et al. Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118:5989\u201395. https:\/\/doi.org\/10.1182\/blood-2011-06-361386.","journal-title":"Blood"},{"key":"3958_CR9","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1200\/JCO","volume":"35","author":"P Moreau","year":"2017","unstructured":"Moreau P, Attal M, Caillot D, et al. Prospective evaluation of magnetic resonance imaging and [18 F]Fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM\/DFCI 2009 trial: Results of the IMAJEM Study. J Clin Oncol. 2017;35:2911\u20138. https:\/\/doi.org\/10.1200\/JCO.","journal-title":"J Clin Oncol"},{"key":"3958_CR10","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","volume":"114","author":"TB Bartel","year":"2009","unstructured":"Bartel TB, Haessler J, Brown TLY, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114:2068\u201376. https:\/\/doi.org\/10.1182\/blood-2009-03-213280.","journal-title":"Blood"},{"key":"3958_CR11","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/j.1600-0609.2009.01399.x","volume":"84","author":"L L\u00f3pez-Anglada","year":"2010","unstructured":"L\u00f3pez-Anglada L, Guti\u00e9rrez NC, Garc\u00eda JL, et al. P53 deletion may drive the clinical evolution and treatment response in multiple myeloma. Eur J Haematol. 2010;84:359\u201361. https:\/\/doi.org\/10.1111\/j.1600-0609.2009.01399.x.","journal-title":"Eur J Haematol"},{"key":"3958_CR12","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/j.1365-2141.2004.05199.x","volume":"127","author":"H Chang","year":"2004","unstructured":"Chang H, Sloan S, Li D, Stewart AK. Multiple myeloma involving central nervous system: High frequency of chromosome 17p13.1 (p53) deletions. Br J Haematol. 2004;127:280\u20134. https:\/\/doi.org\/10.1111\/j.1365-2141.2004.05199.x.","journal-title":"Br J Haematol"},{"key":"3958_CR13","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1002\/hon.3123","volume":"41","author":"J Kauer","year":"2023","unstructured":"Kauer J, Sester LS, Kriegsmann K, et al. Cyclophosphamide etoposide dexamethasone as salvage and bridging therapy in relapsed refractory and extramedullary multiple myeloma. Hematol Oncol. 2023;41:453\u201362. https:\/\/doi.org\/10.1002\/hon.3123.","journal-title":"Hematol Oncol"},{"key":"3958_CR14","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00277-014-2216-8","volume":"94","author":"SE Lee","year":"2015","unstructured":"Lee SE, Kim JH, Jeon YW, et al. Impact of extramedullary plasmacytomas on outcomes according to treatment approach in newly diagnosed symptomatic multiple myeloma. Ann Hematol. 2015;94:445\u201352. https:\/\/doi.org\/10.1007\/s00277-014-2216-8.","journal-title":"Ann Hematol"},{"key":"3958_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.668099","author":"JS He","year":"2021","unstructured":"He JS, Yue XY, He DH, et al. Multiple extramedullary-bone related and\/or extramedullary extraosseous are independent poor prognostic factors in patients with newly diagnosed multiple myeloma. Front Oncol. 2021. https:\/\/doi.org\/10.3389\/fonc.2021.668099.","journal-title":"Front Oncol"},{"key":"3958_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41408-022-00679-5","volume":"12","author":"P Hagen","year":"2022","unstructured":"Hagen P, Zhang J, Barton K. High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions. Blood Cancer J. 2022;12:83. https:\/\/doi.org\/10.1038\/s41408-022-00679-5.","journal-title":"Blood Cancer J"},{"key":"3958_CR17","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u201346. https:\/\/doi.org\/10.1016\/S1470-2045(16)30206-6.","journal-title":"Lancet Oncol"},{"key":"3958_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00730-5","author":"R Jim\u00e9nez-Segura","year":"2022","unstructured":"Jim\u00e9nez-Segura R, Rosi\u00f1ol L, Cibeira MT, et al. Paraskeletal and extramedullary plasmacytomas in multiple myeloma at diagnosis and at first relapse: 50-years of experience from an academic institution. Blood Cancer J. 2022. https:\/\/doi.org\/10.1038\/s41408-022-00730-5.","journal-title":"Blood Cancer J"},{"key":"3958_CR19","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.clml.2014.12.013","volume":"15","author":"S Deng","year":"2015","unstructured":"Deng S, Xu Y, An G, et al. Features of extramedullary disease of multiple myeloma: High frequency of P53 deletion and poor survival: a retrospective single-center study of 834 cases. Clin Lymphoma Myeloma Leuk. 2015;15:286\u201391. https:\/\/doi.org\/10.1016\/j.clml.2014.12.013.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3958_CR20","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3324\/haematol.2019.219295","volume":"105","author":"M Beksac","year":"2020","unstructured":"Beksac M, Seval GC, Kanellias N, et al. A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome. Haematologica. 2020;105:201\u20138. https:\/\/doi.org\/10.3324\/haematol.2019.219295.","journal-title":"Haematologica"},{"key":"3958_CR21","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3324\/haematol.2013.094409","volume":"99","author":"L Pour","year":"2014","unstructured":"Pour L, Sevcikova S, Greslikova H, et al. Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica. 2014;99:360\u20134. https:\/\/doi.org\/10.3324\/haematol.2013.094409.","journal-title":"Haematologica"},{"key":"3958_CR22","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.clml.2022.04.014","volume":"22","author":"DF Moreno","year":"2022","unstructured":"Moreno DF, Clap\u00e9s V, Soler JA, et al. Real-world evidence of daratumumab monotherapy in relapsed\/refractory multiple myeloma patients and efficacy on soft-tissue plasmacytomas. Clin Lymph Myeloma Leuk. 2022;22:635\u201342. https:\/\/doi.org\/10.1016\/j.clml.2022.04.014.","journal-title":"Clin Lymph Myeloma Leuk"},{"key":"3958_CR23","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/bjh.13382","volume":"169","author":"C Varga","year":"2015","unstructured":"Varga C, Xie W, Laubach J, et al. Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. Br J Haematol. 2015;169:843\u201350. https:\/\/doi.org\/10.1111\/bjh.13382.","journal-title":"Br J Haematol"},{"key":"3958_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41375-019-0660-0","volume":"34","author":"M Bhutani","year":"2020","unstructured":"Bhutani M, Foureau DM, Atrash S, et al. Extramedullary multiple myeloma. Leukemia. 2020;34:1\u201320. https:\/\/doi.org\/10.1038\/s41375-019-0660-0.","journal-title":"Leukemia"},{"key":"3958_CR25","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/hon.2958","volume":"40","author":"W Li","year":"2022","unstructured":"Li W, Liu M, Yuan T, et al. Efficacy and follow-up of humanized anti-BCMA CAR-T cell therapy in relapsed\/refractory multiple myeloma patients with extramedullary-extraosseous, extramedullary-bone related, and without extramedullary disease. Hematol Oncol. 2022;40:223\u201332. https:\/\/doi.org\/10.1002\/hon.2958.","journal-title":"Hematol Oncol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-03958-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-03958-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-03958-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T11:18:06Z","timestamp":1750936686000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-03958-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["3958"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-03958-6","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,3]]},"assertion":[{"value":"6 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of \u0130stanbul University Cerrahpa\u015fa (Date: April 7, 2021 and number: 83088843\u2013604.01.01\u201370805).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}